What Is Tilmicosin?
Tilmicosin is a semi-synthetic macrolide antibiotic developed specifically for veterinary medicine. Its molecular formula is C46H80N2O13 and its CAS number is 108050-54-0. The molecule belongs to the 16-membered macrolide family and is structurally related to tylosin and to the erythromycin group. It is approved for use in food-producing animals, mainly cattle, sheep, goats, swine and poultry, where it targets bacterial respiratory disease. Its pharmacokinetic profile shows rapid absorption after injection, extensive distribution into lung tissue and a long elimination half-life, which allows extended dosing intervals under veterinary direction.
Because the compound is a prescription veterinary medicine in most markets, its production and supply are controlled: manufacturers hold the substance to pharmacopoeial specifications and distribute it only as finished, labelled veterinary formulations for use under professional supervision.
How Tilmicosin Works
Tilmicosin binds reversibly to the 50S ribosomal subunit of susceptible bacteria at a site within domain V of the 23S rRNA of the peptidyl transferase centre. Binding blocks the translocation step of peptide elongation, so newly formed peptide chains cannot move from the aminoacyl site to the peptidyl site, and bacterial protein synthesis stops. Because the target is protein synthesis rather than the cell wall or DNA, the primary effect is suppression of bacterial growth and multiplication.
Macrolides such as tilmicosin also concentrate inside phagocytic cells and are released at the site of infection, and they can modulate host immune responses by supporting macrophage and neutrophil function. This combination of direct antibacterial action and immunomodulation contributes to the clinical response observed in respiratory disease.
Bactericidal or Bacteriostatic?
Tilmicosin is classified primarily as a bacteriostatic antibiotic, because its main mode of action is inhibition of bacterial growth rather than direct killing of the bacterial cell. However, at sufficiently high concentrations relative to the minimum inhibitory concentration of the target organism, and against highly susceptible strains, it can exert bactericidal activity. Lung tissue concentrations reached after label-directed administration often exceed the minimum inhibitory concentration for the main respiratory pathogens, which explains why clinical efficacy is observed even though the drug is not a classic bactericidal agent.
The practical answer for prescribers is that the outcome depends on the drug concentration at the site of infection, the bacterial species and the stage of the disease. Early treatment of acute respiratory disease, when the bacterial load is still moderate and the pathogen is fully susceptible, gives the best chance of rapid bacterial clearance. Delayed treatment, deep abscessation or mixed infections limit the effect of any macrolide regardless of its in vitro profile.
Spectrum and Target Pathogens
Mannheimia haemolytica: the principal agent of bovine respiratory disease and the most important target for tilmicosin in feedlot and dairy practice.
Pasteurella multocida: implicated in respiratory disease of cattle and swine, generally highly susceptible.
Histophilus somni: part of the bovine respiratory disease complex, including cases with septicaemia and respiratory signs.
Mycoplasma species: Mycoplasma bovis in cattle, Mycoplasma hyopneumoniae in swine and Mycoplasma gallisepticum in poultry are susceptible, which is relevant because these organisms are not controlled by beta-lactams.
Actinobacillus pleuropneumoniae: a common swine respiratory pathogen, covered by tilmicosin in premix formulations.
Not covered: Enterobacteriaceae such as Escherichia coli and Salmonella, and Pseudomonas aeruginosa, are intrinsically resistant or poorly susceptible, so the product is not indicated for enteric or environmental infections.
Approved Uses in Livestock and Poultry
In cattle, tilmicosin is used to treat and control bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni, including metaphylactic use in groups of animals at high risk of developing the disease. In sheep and goats it is used for respiratory infections caused by susceptible organisms. In swine, premix formulations address respiratory disease linked to Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae and Pasteurella multocida according to local approvals. In poultry, tilmicosin has been applied against certain mycoplasma infections in specific markets.
Approval status, permitted species, dosage forms, dose rates and withdrawal periods differ between countries, and the product is a prescription-only veterinary medicine. The locally approved label and the supervising veterinarian therefore govern every use decision, including dose, route, duration and the interval before slaughter or milk collection.
Product Forms and Quality Parameters
| Parameter | Description |
|---|---|
| Active substance | Tilmicosin base, molecular formula C46H80N2O13, CAS number 108050-54-0 |
| Common salts | Tilmicosin phosphate, used where a more soluble salt is required for formulation |
| Appearance | White to off-white crystalline powder |
| Assay | Determined by high-performance liquid chromatography against the applicable veterinary pharmacopoeial monograph |
| Identification | Infrared absorption and chromatographic retention time against a reference standard |
| Loss on drying and heavy metals | Controlled within the limits set by the applicable monograph |
| Typical presentations | 300 mg/mL injectable solution for cattle and sheep; premix and granule formulations for swine and poultry |
| Storage | Original sealed container, protected from light, stored within the temperature range stated on the approved label |
Safety, Residues and Responsible Use
Prescription status: tilmicosin must be used only under veterinary supervision, with a diagnosis that justifies macrolide therapy.
Species restriction: tilmicosin is cardiotoxic and can be fatal when injected into horses, and it must never be given to species for which it is not approved.
Operator safety: accidental self-injection can cause serious cardiovascular effects; injectable forms must be handled with care and any exposure requires immediate medical attention.
Residue compliance: withdrawal periods for meat and milk must be respected so that residues stay below the maximum residue limits set by the importing market.
Stewardship: correct dose, adequate duration and avoidance of unnecessary group treatment help limit macrolide resistance in animal and human pathogens.
Storage and disposal: keep in the original labelled container, protect from light, and dispose of expired product through approved veterinary pharmaceutical channels.
Frequently Asked Questions
Q: Is tilmicosin bactericidal?
Tilmicosin is primarily bacteriostatic, but it can be bactericidal at higher concentrations against highly susceptible bacteria such as the main respiratory pathogens.
Q: How does tilmicosin work?
It binds to the 50S ribosomal subunit and blocks translocation during protein synthesis, which stops bacterial growth and supports the animal immune response.
Q: What is tilmicosin used for?
It is used to treat and control respiratory infections in cattle, sheep, goats, swine and poultry, depending on local approvals and veterinary prescription.
Q: Can tilmicosin be injected into horses?
No. Tilmicosin is cardiotoxic and can be fatal in horses and other non-target species, and it must never be injected into such animals.
Q: Why is tilmicosin a prescription product?
Because it is a veterinary antibiotic with significant cardiovascular safety risks and resistance concerns, it is regulated as a prescription-only medicine in most countries.
Q: Does tilmicosin cover Mycoplasma infections?
Yes. Mycoplasma bovis, Mycoplasma hyopneumoniae and Mycoplasma gallisepticum are susceptible, which makes it useful where these organisms contribute to respiratory disease.